Age-related disparity in treatment outcome and adverse events among patients with metastatic colorectal cancer (mCRC).

被引：0
|
作者：
Meng, Lingbin [1 ]
Thapa, Ram [1 ]
Xie, Hao [1 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6204
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Disparity of treatment-related adverse events and outcome in patients with early-onset metastatic colorectal cancer (mCRC).
    Meng, Lingbin
    Thapa, Ram
    Kim, Richard D.
    Laber, Damian A.
    Xie, Hao
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Association of Age With Treatment-Related Adverse Events and Survival in Patients With Metastatic Colorectal Cancer
    Meng, Lingbin
    Thapa, Ram
    Delgado, Maria G.
    Gomez, Maria F.
    Ji, Rui
    Knepper, Todd C.
    Hubbard, Joleen M.
    Wang, Xuefeng
    Permuth, Jennifer B.
    Kim, Richard D.
    Laber, Damian A.
    Xie, Hao
    [J]. JAMA NETWORK OPEN, 2023, 6 (06) : E2320035
  • [3] Age-related real-world outcomes for patients (pts) with metastatic colorectal cancer (mCRC).
    Curtis, Melissa
    Nussbaum, Nathan Coleman
    Hamrick, Harvey J.
    Bennette, Caroline Savage
    Meropol, Neal J.
    Miksad, Rebecca A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Treatment of metastatic colorectal cancer (mCRC) according to age
    Ortega, Laura
    Torres Perez-Solero, Gabriela
    Arregui Valles, Marta
    Alva Bianchi, Manuel
    Aparicio Salcedo, Inmaculada
    Garcia Gonzalez, Gonzalo
    Gallego Gallego, Iria
    Munoz Martin, Andres J.
    Calvo Ferrandiz, Aitana
    Blanco-Codesido, Montserrat
    Martin, Miguel
    Garcia-Alfonso, Pilar
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [5] FREQUENCY AND COSTS ASSOCIATED WITH TARGETED THERAPY-RELATED ADVERSE EVENTS (AES) DURING FIRST AND SECOND LINE OF TREATMENT (LOT) AMONG PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC)
    Byfield, DaCosta S.
    Langer, C.
    Ogale, S.
    Morlock, R.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A80 - A81
  • [6] Treatment with bevacizumab in patients with metastatic colorectal cancer (mCRC)
    Ocvirk, Janja
    Rebersek, Martina
    Boc, Marko
    Motara, Maja Ebert
    Mesti, Tanja
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] Adverse events (AE) following diagnosis (Dx) in older metastatic colorectal cancer (mCRC) patients (Pts)
    Shankaran, Veena
    Mummy, David G.
    Blough, David K.
    Koepl, Lisel
    Yim, Yeun Mi
    Yu, Elaine
    Ramsey, Scott David
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] ADVERSE EVENTS (AES) ASSOCIATED WITH BEVACIZUMAB (BV) IN OLDER PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Shankaran, V.
    Mummy, D.
    Koepl, L.
    Blough, D.
    Yim, Y. M.
    Yu, E.
    Ramsey, S.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 203 - 203
  • [9] Impact of RAS testing on treatment duration among patients with metastatic colorectal cancer (mCRC).
    Bach, Bruce A.
    Christodoulopoulou, Alexandra
    Klink, Andrew
    Hechmati, Guy
    Mujumdar, Urvi
    Feinberg, Bruce A.
    Fakih, Marwan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [10] HOSPITAL COSTS OF ADVERSE EVENTS IN PATIENTS RECEIVING TREATMENT FOR METASTATIC COLORECTAL CANCER
    Fu, A. Z.
    Zhao, Z.
    Wang, S.
    Gao, S.
    Barber, B.
    Liu, G.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A173 - A173
12345